# Kinnjiu

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kinnjiu

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.kinnjiu.com
- Total disclosed funding: $35M
- Latest round: Series A (Jan 7, 2022)
- Investors on record: 3

## About

Founded in 2021 and based in Shanghai, China, Kinnjiu is a biopharmaceutical company that focuses on the research and development of oncology drugs that are exclusively licensed by Kinnate Biopharma Inc. The company is jointly invested and established by Kinnate Biopharma Inc., OrbiMed Asia Fund, OrbiMed Capital and Foresite Capital. In February 2023, Kinnate Biopharma, Inc. acquired a USD 24 million stake in Kinnjiu from Foresite Capital and OrbiMed Advisors. Kinnate Biopharma, Inc. already owns 100% of the company's shares.

The company's main products include pan-RAF kinase inhibitors, small molecule kinase inhibitors and CDK12 drugs. Its products are used in lung cancer, melanoma, bowel cancer and other diseases.

## Funding rounds

- Series A, Jan 7, 2022, $35M — OrbiMed Advisors, Foresite Capital, Kinnate Biopharma, Inc.

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A
- Kinnate Biopharma, Inc. — Series A